Last updated on November 2016

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer


Brief description of study

This phase Ib/II trial studies how well ibrutinib and nivolumab work in treating patients with previously-treated kidney cancer that has spread to other parts of the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving Ibrutinib and nivolumab may work better in treating patients with metastatic kidney cancer.

Detailed Study Description

PRIMARY OBJECTIVE: To assess in a preliminary fashion the feasibility and efficacy of ibrutinib in combination with nivolumab in patients with previously-treated metastatic renal cell cancer (mRCC). SECONDARY OBJECTIVE: To evaluate the safety of the combination of ibrutinib and nivolumab in patients with previously treated mRCC.

Clinical Study Identifier: NCT02899078

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Primo N. Lara, M.D.

University of California Davis Comprehensive Cancer Center
Sacramento, CA United States
  Connect »